Korro

IPO

Editing RNA to rewrite the future of medicine

Public · Cambridge, United States · Founded 2019 · $271.0M raised

Employees
51–200
Founded
2019
Business Model
B2B
Total Funding
$271.0M
Last Round
$85.0M Private EquityMar 2026
Rounds
4
Type
Public

About

Korro Bio is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing a new class of genetic medicines based on editing RNA. By leveraging endogenous RNA editing mechanisms, Korro's platform enables treatment of both rare and highly prevalent diseases. The company's lead program KRRO-110 targets alpha-1 antitrypsin deficiency (AATD). Founded in 2019 out of Atlas Venture, Korro merged with Frequency Therapeutics in 2023 and listed on Nasdaq (KRRO).

Summary

Korro is a Biotech company based in Cambridge, United States, founded in 2019. It has raised $271.0M in total across 4 rounds, most recently a $85.0M Private Equity round in Mar 2026. Investors include New Enterprise Associates, Atlas Venture and Venrock.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Sign up to view the funding chart

Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.

Private EquityPrivate EquityMar 2026
$85.0M

Sign up to see all 4 rounds

Venture Round through Private Equity — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Korro on Indexed.vc
<a href="https://indexed.vc/companies/korro"><img src="https://indexed.vc/api/badge/company/korro" alt="Korro on Indexed.vc" width="260" height="76" /></a>